Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05557045
Other study ID # JZP815-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 10, 2022
Est. completion date April 1, 2028

Study information

Verified date May 2024
Source Jazz Pharmaceuticals
Contact Clinical Trial Disclosure & Transparency
Phone 215-832-3750
Email ClinicalTrialDisclosure@JazzPharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.


Description:

This first-in-human study will consist of two parts: Part A and Part B. Part A will characterize the safety and tolerability of JZP815, assess pharmacokinetics (PK) profile, and determine a recommended phase 2 dose (RP2D) to be further investigated in the Expansion phase (Part B). Part B will further investigate the RP2D determined in Part A, and assess antitumor activity in various subsets of disease (based on mutation and/or tumor type) in which the mechanism of action of JZP815 is applicable.


Recruitment information / eligibility

Status Recruiting
Enrollment 332
Est. completion date April 1, 2028
Est. primary completion date April 1, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant must be = 18 years of age, at the time of signing the informed consent - Participants who have histological or cytological diagnosis of an advanced or metastatic solid tumor carrying a documented, clinically significant, MAPK pathway alteration - Participants must have exhausted all available standard of care therapies, or in the opinion of the investigator would be unlikely to tolerate or derive clinically meaningful benefit from available standard of care therapy - Performance status (ECOG) of 0 or 1, measured within 72 hours before start of treatment - Must have measurable disease by RECIST v1.1 - Tumor must be safely amenable to core needle or excisional biopsy (applies only to participants enrolled in Pre-Expansion cohorts) - Adequate organ function - Expected life expectancy of at least 12 weeks - For each arm in Part B (Expansion), participant must be diagnosed with the tumor type(s) carrying the mutation(s) specified and meet protocol specified requirements for prior therapy - Male participants must agree to refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use contraception - Female participants are eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: is a women of nonchildbearing potential (WONCBP) or is a women of childbearing potential (WOCBP) and using a contraceptive method that is highly effective during the study intervention period and for at least 3 months after the last dose of study intervention and agrees not to donate eggs - A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) within 3 days before the first dose of study intervention - Capable of giving signed informed consent Exclusion Criteria: - Known uncontrolled brain metastases. Stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants, with no dose change in the previous 4 weeks, are permitted - Active fungal, bacterial and/or known viral infection including HIV or Hepatitis A, B, C - Concomitant malignancies or previous malignancies with less than 2 years disease-free interval at the time of enrollment, with the exception of non-metastatic, non-melanomatous skin cancers, carcinoma in-situ, melanoma in-situ, prostate cancer with undetectable PSA that are adequately treated - Has clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), QTc = 470 msec, or serious cardiac arrhythmia requiring medication - Uncontrolled or severe intercurrent medical condition - Gastrointestinal condition that could impair absorption of study intervention or inability to ingest study intervention - In the judgement of the investigator, any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study - Received any cancer directed therapy (chemotherapy, hormonal therapy, biologic, etc.) within 28 days or 5 half-lives (whichever is shorter) of starting study intervention. Participants who have received radiotherapy must have recovered from acute toxicities associated with treatment. - Use of any products or medicines known to be strong or moderate inducers or inhibitors of CYP3A4, which cannot be discontinued at least 4 weeks or 5 half-lives (whichever is shorter) before starting study intervention, or planned use at any time during the study - Use of proton pump inhibitors and histamine-2 receptor antagonists, which cannot be discontinued at least 2 weeks before first dose, or planned use at any time during the study - Concurrent therapy with any other investigational agent

Study Design


Intervention

Drug:
JZP815
JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.

Locations

Country Name City State
United States University of Chicago Chicago Illinois
United States SCRI HealthOne Denver Colorado
United States Tennessee Oncology - Nashville Nashville Tennessee
United States Icahn School of Medicine at Mount Sinai New York New York
United States Oklahoma University Oklahoma City Oklahoma
United States Florida Cancer Specialists - Lake Nona Orlando Florida
United States Sidney Kimmel Cancer Center Philadelphia Pennsylvania
United States Florida Cancer Specialists - Sarasota Sarasota Florida

Sponsors (1)

Lead Sponsor Collaborator
Jazz Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Dose-Limiting Toxicities (Part A) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Hemoglobin (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Absolute Neutrophil Count (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Platelets (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Hematocrit (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Aspartate Aminotransferase (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Alanine Aminotransferase (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Creatinine (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Total Bilirubin (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Heart Rate (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Change From Baseline in Blood Pressure (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Number of Participants With Dose Interruptions and Reductions (Part A and B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Objective Response Rate (as Defined by RECIST v1.1) (Part B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary Duration of Response (Part B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Secondary Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP815 and its Metabolites (Part A) AUC from time 0 to infinity (AUCinf) and AUC during a dosing interval (AUCtau) will be assessed. Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Pharmacokinetic Parameter Clearance (CL/F) of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Pharmacokinetic Parameter Accumulation Ratio of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Pharmacokinetic Parameter Apparent Volume of Distribution During Terminal Phase (Vz/F) of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Pharmacokinetic Parameter Metabolite to Parent Ratio of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Dose Proportionality of JZP815 and its Metabolites (Part A) Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary Objective Response Rate (as Defined by RECIST v1.1) (Part A) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Secondary Progression-free Survival (Part B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Secondary Overall Survival (Part B) Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2